Oramed Pharmaceuticals Inc. (ORMP) news stock charts
Oramed Pharmaceuticals Inc. (ORMP/ORMP.OB) Investment Summary:
Oramed Pharmaceuticals, Inc., a development stage company, engages in the research and development of pharmaceutical solutions. The company is developing orally ingestible insulin pill capsules for the treatment of individuals with diabetes. It also focuses on conducting research and development of other pharmaceutical solutions, including rectal application of insulin, flu vaccines, use of oral ingestible pills for delivery other polypeptides, and use of rectal application for delivery of other polypeptides. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals, Inc. in 2006. Oramed Pharmaceuticals is based in Jerusalem, Isra...www.oramed.com
Founded in 2002
ORAMED PHARMACEUTICALS INC (ORMP:OTC Bulletin Board Market)
LAST $0.43 USD
CHANGE TODAY 0.00 0.00%
VOLUME 1.2K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of ORAMED PHARMACEUTICALS INC (ORMP)
|
OPEN
$0.43
|
PREVIOUS CLOSE
$0.43
|
|
|
DAY HIGH
$0.43
|
DAY LOW
$0.43
|
|
|
52 WEEK HIGH
09/8/09 - $0.64
|
52 WEEK LOW
03/27/09 - $0.26
|
|
|
MARKET CAP
24.5M
|
AVERAGE VOLUME 10 D
9.5K
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
57.0M
|
|
|
ORMP Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for ORAMED PHARMACEUTICALS INC (ORMP)
Oramed Pharmaceuticals Inc. Appoints John M. Amatruda to Scientific Advisory Board
02/16/2010
Oramed Pharmaceuticals Inc. announced that John M. Amatruda, M.D. has joined the company's Scientific Advisory Board, enhancing Oramed's talented and experienced scientific team. Dr. Amatruda was the Senior Vice President and Franchise Head, Diabetes and Obesity at Merck Research Laboratories. He is board certified in internal medicine, endocrinology and metabolism and has a proven track record in academics and pharmaceutical discovery research and development, including several novel candidate compounds, INDs, translational studies, development programs and four NDAs. In joining the Scientific Advisory Board, Dr. Amatruda will provide Oramed access to his extensive successful pharmaceutical industry experience in the development and approval of novel drugs. Additionally, his experience in licensing, structuring agreements and managing collaborations will prove invaluable to the company.
Oramed Pharmaceuticals Inc. Presents at Third International Conference on Advanced Technologies and Treatments for Diabetes in 2010, Feb-11-2010 through Feb-13-2010
02/1/2010
Oramed Pharmaceuticals Inc. Presents at Third International Conference on Advanced Technologies and Treatments for Diabetes in 2010, Feb-11-2010 through Feb-13-2010. Venue: Congress Center Basel, MCH Messe Schweiz (Basel) AG, CH - 4005 Basel, Swaziland. Speakers: Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director.
Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
01/19/2010
Oramed Pharmaceuticals Inc. announced the completion of patient enrollment in the Phase 2B clinical study of its oral insulin capsule, ORMD-0801. The last of the thirty Type II diabetes patients was enrolled for a study in which subjects will be administered the insulin-based capsule for a period of six weeks. The randomized, double-blind, placebo-controlled, multi-centered study will evaluate the safety, tolerability, and efficacy of Oramed's oral insulin delivery technology. The study is taking place in five locations throughout South Africa and is being monitored by OnQ Consulting, a clinical research organization (CRO) based in Johannesburg, South Africa. Study results are expected by the end of first quarter of 2010. This trial marks an important milestone in ORMD-0801 safety testing, assessing the first indication of ORMD-0801 on a large group of volunteers over an extended treatment period.
Oramed Pharmaceuticals Inc. financial resources
ORMP Competitors
| Company | Last | Change | |
| No competitor information is available for ORMP. | |||
| Market data is delayed at least 15 minutes. | |||
Industry Analysis
| Valuation | ORMP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 10.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ORMP |
||
ORMP transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
2010-02-19 01:14:08
Quote: JERUSALEM, Israel, January 19 /PRNewswire-FirstCall/ --- Key Trial for Oral Insulin With Expected Results at the End of Q1 of
2010Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today the
completion of patient enrollment in the Phase 2B clinical study of its oral
insulin capsule, ORMD-0801. The last of the thirty Type II diabetes patients
was enrolled for a study in which subjects will be administered the
insulin-based capsule for a period of six weeks.The randomized, double-blind, placeb...Read article
Oramed Pharmaceuticals Announces Filing of Two Registration Statements
2010-02-19 01:14:08
Quote: This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities, in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.About Oramed PharmaceuticalsOramed Pharmaceuti......Read article
Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
2010-02-19 01:14:07
Quote: Amatruda is joined on the Scientific Advisory Board by the following
existing members: Derek LeRoith, Ph.D.; Nir Brazilai, M.D.; Ele Ferrannini,
M.D., Ph.D.; and Avram Hershko, M.D., Ph.D.About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its......Read article
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
2010-02-19 01:14:07
Quote: Results are expected at the
end of the first quarter of 2010.About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top resea...Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2010-02-18 07:45:13
Quote: ITEM 7.01 REGULATION FD DISCLOSURE
On February 16, 2010, Oramed Pharmaceuticals Inc. issued a press release
announcing that John M. Amatruda, M.D. has joined Oramed's Scientific Advisory
Board, enhancing Oramed's talented and experienced scientific team.
Dr. Amatruda was the Senior Vice President and Franchise Head, Diabetes and
Obesity at Merck Research Laboratories. He is board certified in internal
medicine, endocrinology and metabolism and has a proven track record in
academics and pharmace...Read article
Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
2010-02-17 08:43:56
Quote: Amatruda is joined on the Scientific Advisory Board by the following
existing members: Derek LeRoith, Ph.D.; Nir Brazilai, M.D.; Ele Ferrannini,
M.D., Ph.D.; and Avram Hershko, M.D., Ph.D.About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its......Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2010-02-12 06:36:42
Quote: ORAMED PHARMACEUTICALS INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
ORAMED PHARMACEUTICALS INC.
11-Feb-2010Regulation FD Disclosure, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is lia...Read article
Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
2010-02-11 04:19:33
Quote: Results are expected at the
end of the first quarter of 2010.About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of research by top resea...Read article
Oramed Pharmaceuticals Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
2010-01-20 01:58:55
Quote: JERUSALEM, Israel, January 19 /PRNewswire-FirstCall/ --- Key Trial for Oral Insulin With Expected Results at the End of Q1 of
2010Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today the
completion of patient enrollment in the Phase 2B clinical study of its oral
insulin capsule, ORMD-0801. The last of the thirty Type II diabetes patients
was enrolled for a study in which subjects will be administered the
insulin-based capsule for a period of six weeks.The randomized, double-blind, placeb...Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
2010-01-14 03:21:40
Quote: In addition, the SEC maintains an internet site (www.sec.gov)
that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC, including us.
As used in this Quarterly Report, the terms "we", "us", "our", "Company" and
"Oramed" mean Oramed Pharmaceuticals Inc. and our subsidiary, Oramed Ltd.,
unless otherwise indicated.
All dollar amounts refer to US dollars unless otherwise in...Read article
Oramed Pharmaceuticals Announces Filing of Two Registration Statements
2010-01-12 01:59:45
Quote: This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities, in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.About Oramed PharmaceuticalsOramed Pharmaceuti......Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2010-01-12 01:59:44
Quote: ITEM 7.01 REGULATION FD DISCLOSURE
On January 11, 2010, Oramed Pharmaceuticals Inc. issued a press release
announcing that it had filed two registration statements on Form S-1 with the
Securities and Exchange Commission.
One registration statement relates to a proposed public offering by Oramed of 24
million shares of common stock and warrants to purchase 12 million shares of
common stock, as well as warrants to purchase up to approximately 2.5 million
shares of common stock issuable to the pla...Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2010-01-07 02:31:20
Quote: ORAMED PHARMACEUTICALS INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
ORAMED PHARMACEUTICALS INC.
6-Jan-2010Regulation FD Disclosure, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liab...Read article
Oramed Pharmaceuticals to Present at OneMedPlace Finance Forum in San Francisco, California
2010-01-06 02:01:45
Quote: He will discuss the company's strategic
initiatives, company updates and Oramed's product pipeline.About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
...Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2010-01-05 01:18:45
Quote: ORAMED PHARMACEUTICALS INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
ORAMED PHARMACEUTICALS INC.
4-Jan-2010Regulation FD Disclosure, Financial Statements and Exhibits
Privacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liab...Read article
Oramed's Dr Roy Eldor was Chosen to Lecture at the First International Conference Held by the Bildirici Center for Diabetes Care Research in Israel.
2009-12-23 01:02:18
Quote: Updates
and overviews will be given by invited speakers from around the world,
together with workshop and debate sessions and submitted oral and poster
presentations.http://www.diabetescenter.org.ilAbout Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin ...Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2009-12-09 04:26:58
Quote: ITEM 7.01 REGULATION FD DISCLOSURE
On August 4, 2009, Oramed Pharmaceuticals Inc. (the "Company") issued a press
release reporting that its wholly owned Israeli subsidiary, Oramed Ltd., was
awarded a government grant amounting to a total net amount of NIS 3.1 million
($828,000), from the Office of the Chief Scientist (OCS) at the Ministry of
Industry, Trade and Labor of Israel. This grant was awarded as government
participation in research and development expenses for the period of Fe...Read article
Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
2009-11-30 01:23:56
Quote: He will discuss Oramed's strategic initiatives, updates
and product pipeline.About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
phase 2 clinical trials. Established in 2006, Oramed's technology is based on
over 25 years of resea...Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2009-11-30 01:23:56
Quote: ORAMED PHARMACEUTICALS INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
ORAMED PHARMACEUTICALS INC.
25-Aug-2009Regulation FD Disclosure, Financial Statements and Exhibits
Privacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any i...Read article
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
2009-11-30 01:23:56
Quote: ORAMED PHARMACEUTICALS INC.Request a Trial to NEW EDGAR Online Pro
Form
8-K for
ORAMED PHARMACEUTICALS INC.
19-Aug-2009Regulation FD Disclosure, Financial Statements and Exhibits
Privacy PolicyTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any i...Read article
Would you like to leave a comment about Oramed Pharmaceuticals Inc. ORMP/ORMP.OB
Find out what social network information about Oramed Pharmaceuticals Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Oramed Pharmaceuticals Inc.'s Stock there is more great penny stock and market information at Realpennies